Тидутамаб

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

2148354-90-7

immunoglobulin half-G1-kappa/scFv-h-CH2-CH3, anti- [Homo sapiens SSTR2 (somatostatin receptor 2) and Homo sapiens CD3 epsilon (CD3E, Leu-4)], monoclonal antibody, bispecific;
gamma1 heavy chain anti-SSTR2 (1-451) [VH (Homo sapiens IGHV3-48*03 (90.8%) -(IGHD) -IGHJ4*01 (100%)) [8.8.15] (1-122) -Homo sapiens IGHG1*03v (CH1 N114>D (213), R120>K (219) (123-220), hinge 1-15 (221-235), CH2 E1.4>P (238), L1.2>V (239), G1.1>A (240), S29>K (271), Q84.2>E (299) (236-344), CH3 E12 (360), M14 (362), L24>D (372), K26>S (374), N44>D (388), Q97>E (422), N100>D (425) (345-449), CHS (450-451)) (123-451)], (225-219')- disulfide with kappa light chain anti-SSTR2 (1'-219') [V-KAPPA (Homo sapiens IGKV4-1*01 (91.8%) - IGKJ4*01 (100.0%)) [12.3.8] (1'-112') -Homo sapiens IGKC*01 (100%) A45.1 (158), V101 (196) (113'-219')]; heavy chain scFv-h-CH2-CH3, anti-CD3E (1-485) [VH (Homo sapiens IGHV3-73*01 (87.0%) -(IGHD) - IGHJ6*01 (90.9%)) [8.10.16] (1-125) -20-mer linker (126-145) -V-LAMBDA (Mus musculus IGLV1*01 (80.6%) -IGLJ1*01 (100%)/Homo sapiens IGLV7- 46*01 (76.8%) -IGHJ3*02 (100%)) [9.3.9] (146-254) - IGHG1*03 (hinge 1-15 C5>S (259) (255-269) -CH2 E1.4>P (272), L1.2>V (273), G1.1>A (274), S29>K (305) (270-378),CH3 E12 (394), E13>Q (395), M14 (396), S20>K (402)(379-483), CHS (484-485)) (1- 485)]; (231-265'':234-268'')-bisdisulfide

Поделиться этой страницей